Omeros (NASDAQ:OMER) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Omeros (NASDAQ:OMER) in a report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $9.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Omeros’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.78) EPS and FY2026 earnings at ($1.14) EPS.

A number of other research analysts have also weighed in on OMER. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, June 6th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, May 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Omeros Stock Down 1.9%

Shares of Omeros stock opened at $3.55 on Tuesday. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The firm has a market cap of $208.01 million, a PE ratio of -1.54 and a beta of 2.20. The business’s fifty day moving average is $5.16 and its two-hundred day moving average is $7.80.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). Equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OMER. Nomura Holdings Inc. raised its position in shares of Omeros by 136.2% in the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in Omeros in the fourth quarter valued at about $1,488,000. Wellington Management Group LLP purchased a new position in Omeros in the first quarter valued at about $1,118,000. Nuveen LLC purchased a new position in Omeros in the first quarter valued at about $938,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Omeros in the fourth quarter valued at about $1,120,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.